UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 441

Sortiert nach

Accelerating progress from advanced to early breast Cancer

Breast (Edinburgh), 2021-04, Vol.56, p.S4

Rugo, H.

2021

Link zum Volltext

Verfügbarkeit prüfen

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

Annals of oncology, 2021-12, Vol.32 (12), p.1475-1495

2021

Link zum Volltext

Verfügbarkeit prüfen

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

Annals of oncology, 2021-08, Vol.32 (8), p.983-993

2021

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study

Annals of oncology, 2022-06, Vol.33 (6), p.616-627

2022

Link zum Volltext

Verfügbarkeit prüfen

The efficacy, challenges, and facilitators of telemedicine in post-treatment cancer survivorship care: an overview of systematic reviews

Annals of oncology, 2021-12, Vol.32 (12), p.1552-1570

2021

Link zum Volltext

Verfügbarkeit prüfen

Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer

ESMO open, 2022-08, Vol.7 (4), p.100553-100553, Article 100553

2022

Link zum Volltext

Verfügbarkeit prüfen

Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial

Annals of oncology, 2018-10, Vol.29, p.viii709-viii709

2018

Link zum Volltext

Verfügbarkeit prüfen

Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial

European journal of cancer (1990), 2018-11, Vol.104, p.160-168

2018

Link zum Volltext

Verfügbarkeit prüfen

Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials

Annals of oncology, 2022-08, Vol.33 (8), p.814-823

2022

Link zum Volltext

Verfügbarkeit prüfen

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Annals of oncology, 2017-12, Vol.28 (12), p.3111-3111

2017

Link zum Volltext

Verfügbarkeit prüfen

High-dimensional immune cell profiling of cerebrospinal fluid from patients with metastatic breast cancer and leptomeningeal disease

NPJ breast cancer, 2023-04, Vol.9 (1), p.22-9, Article 22

2023

Link zum Volltext

Verfügbarkeit prüfen

SA 2.4 - Accelerating progress from advanced to early breast Cancer

Breast (Edinburgh), 2021-04, Vol.56, p.S4-S4

Rugo, H.

2021

Link zum Volltext

Verfügbarkeit prüfen

Settings-based efficacy comparison of trastuzumab biosimilars in breast cancer: A systematic literature review

Annals of oncology, 2018-10, Vol.29, p.viii104-viii104

2018

Link zum Volltext

Verfügbarkeit prüfen

Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation

Annals of oncology, 2018-10, Vol.29, p.viii91-viii91

2018

Link zum Volltext

Verfügbarkeit prüfen

IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC)

Annals of oncology, 2018-10, Vol.29, p.viii707-viii708

2018

Link zum Volltext

Verfügbarkeit prüfen

Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2- advanced breast cancer: Analysis of the MONARCH trials

Annals of oncology, 2018-10, Vol.29, p.viii110-viii111

2018

Link zum Volltext

Verfügbarkeit prüfen

EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis

Annals of oncology, 2018-10, Vol.29, p.viii96-viii97

2018

Link zum Volltext

Verfügbarkeit prüfen

P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes

Breast (Edinburgh), 2023-04, Vol.68, p.S22-S23

2023

Link zum Volltext

Verfügbarkeit prüfen

ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)

Annals of oncology, 2018-10, Vol.29, p.viii118-viii118

2018

Link zum Volltext

Verfügbarkeit prüfen

EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment

Annals of oncology, 2018-10, Vol.29, p.viii96-viii96

2018

Link zum Volltext

Verfügbarkeit prüfen

Treatment selection for patients with low and equivocal ER status

Breast (Edinburgh), 2019-03, Vol.44, p.S7

Rugo, H.

2019

Link zum Volltext

Verfügbarkeit prüfen

SA 6.2 - Treatment selection for patients with low and equivocal ER status

Breast (Edinburgh), 2019-03, Vol.44, p.S7-S7

Rugo, H.

2019

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

The New England journal of medicine, 2022-07, Vol.387 (3), p.217-226

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcomes in patients (pts) with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC) with objective response (OR) or without objective response (non-OR) in PALOMA-2

Annals of oncology, 2018-10, Vol.29, p.viii107-viii108

2018

Link zum Volltext

Verfügbarkeit prüfen

Safety outcomes from monarchE: Phase 3 study of abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer

Breast (Edinburgh), 2021-04, Vol.56, p.S23-S24

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 441

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(440)
Mit Volltextzugriff
(439)

Publikationsform

Artikel
(440)
Tagungsberichte
(1)

Sprache

Englisch
(441)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Science & Technology
(22)
Life Sciences & Biomedicine
(21)
Oncology
(21)
Hematology, Oncology And Palliative Medicine
(17)
Breast Cancer
(12)
Anesthesia & Perioperative Care
(6)
Pain Medicine
(6)
Cancer
(5)
Cancer Therapies
(4)
Chemotherapy
(4)
Life Sciences
(4)
Original Research
(4)
Tumors
(4)
Patients
(3)
Cancer Research
(2)
Confidence Intervals
(2)
Diabetes
(2)
Diagnosis
(2)
Diseases
(2)
Drug Dosages
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancer Research
(153)
Journal Of Clinical Oncology
(105)
Annals Of Oncology
(101)
European Journal Of Cancer
(16)
Breast
(12)
Esmo Open
(10)
European Journal Of Cancer Supplements
(6)
The Journal Of Pain
(6)
Clinical Cancer Research
(3)
Journal Of Investigative Medicine
(3)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Accelerating progress from advanced to early breast Cancer

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study

The efficacy, challenges, and facilitators of telemedicine in post-treatment cancer survivorship care: an overview of systematic reviews

Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer

Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial

Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial

Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

High-dimensional immune cell profiling of cerebrospinal fluid from patients with metastatic breast cancer and leptomeningeal disease

SA 2.4 - Accelerating progress from advanced to early breast Cancer

Settings-based efficacy comparison of trastuzumab biosimilars in breast cancer: A systematic literature review

Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation

IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC)

Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2- advanced breast cancer: Analysis of the MONARCH trials

EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis

P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes

ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)

EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment

Treatment selection for patients with low and equivocal ER status

SA 6.2 - Treatment selection for patients with low and equivocal ER status

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Clinical outcomes in patients (pts) with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC) with objective response (OR) or without objective response (non-OR) in PALOMA-2

Safety outcomes from monarchE: Phase 3 study of abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer

Aktive Filter

Suchergebnisse filtern